8-K: Medifast Reports Q2 2026 Results: Revenue Down, Net Loss Widens

Medifast announced second quarter 2026 results showing a 27.6% revenue decrease to $76.4 million and a net loss of $3.1 million, impacted by a significant drop in active coaches.

Summary

• Medifast reported second quarter 2026 revenue of $76.4 million, a decrease of 27.6% compared to $105.6 million in the prior year's second quarter.
• The company experienced a net loss of $3.1 million, or $0.28 loss per diluted share, compared to a net income of $2.5 million, or $0.22 per share, in the second quarter of 2025.
• The number of independent active earning coaches decreased by 48.7% to 11,700 from 22,800 in the prior year period.
• Average revenue per active earning coach increased by 41.0% to $6,529 from $4,630.
• Gross profit margin decreased to 69.9% from 72.6% due to loss of leverage on fixed costs.
• Selling, general, and administrative (SG&A) expenses decreased by 25.7% to $57.7 million, but as a percentage of revenue, increased to 75.6% from 73.6%.
• The company ended the quarter with $169.8 million in cash, cash equivalents, and investment securities and no debt.
• Medifast expects third quarter 2026 revenue between $60 million and $80 million, and a loss per share between $0.15 and $0.65.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to significant revenue and net loss declines, despite some positive operational metrics and a strong cash position. The outlook remains challenging with continued expected declines in active coaches.

Positives

• Revenue per active earning coach increased significantly by 41.0% to $6,529, indicating improved productivity among remaining coaches.
• The company maintains a strong balance sheet with $169.8 million in cash, cash equivalents, and investment securities and no debt as of June 30, 2026.
• New initiatives like the Trilivy brand, Reset Fuelings, and the Medifast Metabolic Health Institute are being implemented as part of the 3.0 strategy.
• Management notes sequential stability in revenue and positive trends in coach productivity and leadership, suggesting signs of a turnaround.
• The Catalyst program is being executed to drive cost savings through facility rationalization and AI efficiencies.

Negatives

• Revenue for the second quarter of 2026 decreased by 27.6% to $76.4 million compared to $105.6 million in the prior year.
• The number of active earning coaches dropped by 48.7% to 11,700, significantly impacting overall revenue.
• The company reported a net loss of $3.1 million ($0.28 per diluted share) for the quarter, a reversal from a net income of $2.5 million ($0.22 per diluted share) in Q2 2025.
• Gross profit margin declined to 69.9% from 72.6% due to a loss of leverage on fixed costs.
• SG&A expenses, as a percentage of revenue, increased to 75.6% from 73.6% due to loss of leverage on fixed costs.
• Loss from operations was $4.3 million, compared to a loss of $1.1 million in the prior year period.
• The company expects the number of active earning coaches to continue to decline in 2026.

Risks

• Continued pressure with client acquisition reflecting broader challenges in the operating environment, including rapid adoption of GLP-1 medications for weight loss.
• Expectation that the number of active earning coaches will continue to decline in 2026.
• Loss of leverage on fixed costs impacting gross profit margin and SG&A as a percentage of revenue.
• Competition from new weight loss products and services, including GLP-1 medications.
• Potential for online security risks and cyberattacks.
• Competitors' use of artificial intelligence to enhance their offerings.
• Disruptions in the supply chain.
• Product liability claims and adverse publicity associated with products.

Future Outlook

Medifast projects third quarter 2026 revenue to be between $60 million and $80 million, with a loss per share ranging from $0.15 to $0.65. For the full year 2026, revenue is expected to be between $270 million and $300 million, with a loss per share between $0.25 and $1.75. The company anticipates returning to profitability in the fourth quarter of 2026.

Management Comments

• "In the second quarter, we continued to see signs of a turnaround in our business. Revenue remained sequentially stable, supported by steady growth in coach productivity and positive coach leadership trends."
• "Combined with the energy and engagement demonstrated at our recent National Coach Convention, these leading indicators have historically been precursors of future growth."
• "We're building on that progress by putting new tools in our coaches' hands, with our new brand, Trilivy, our new Reset Fuelings, and our new Medifast Metabolic Health Institute. Each of these is a meaningful step in our 3.0 strategy."
• "Backed by our Metabolic Synchronization science and coach-led model, we believe we are on track to return to profitability in the fourth quarter and have created a foundation that supports our vision for consistent, long-term growth."

Industry Context

StockSavvy.ai notes that Medifast's challenges, particularly the decline in active coaches and client acquisition pressures, are exacerbated by the broader industry trend of rapid adoption of GLP-1 medications for weight loss, which directly competes with traditional weight management systems.

Stakeholder Impact

• Shareholders: Negative impact due to decreased revenue, net loss, and a challenging outlook, potentially affecting stock price.
• Employees: Potential impact from cost-saving initiatives like facility rationalization and AI efficiencies, which could lead to restructuring.
• Coaches: Negative impact from the significant decline in active coaches and continued expected decline, affecting their earnings potential.
• Customers: May face challenges with client acquisition and potentially shifting preferences towards newer weight loss solutions like GLP-1s.

Next Steps

• Continue execution of the 3.0 strategy with new brand Trilivy, Reset Fuelings, and Medifast Metabolic Health Institute.
• Implement the Catalyst program in Q3 2026 for cost savings through facility rationalization and AI efficiencies.
• Focus on returning to profitability in the fourth quarter of 2026.
• Support long-term growth through Metabolic Synchronization science and a coach-led model.

Key Dates

Recommendation

The significant year-over-year decline in revenue and the shift from profit to a substantial net loss, coupled with a nearly 50% reduction in the active coach base and ongoing expected declines, present considerable headwinds. While the company has a strong cash position and is implementing strategic initiatives, the current operational performance and outlook suggest a period of continued struggle, making it prudent for investors to consider reducing their exposure.

Keywords

Medifast, Trilivy, Metabolic Health, Weight Loss, Earnings, Revenue, Coaches, GLP-1